在线客服: 点击这里给我发消息  新用户使用步骤:会员注册→充值→重新登入→进入资源
标题:Serum carcinoembryonic antigen levels predicts the efficacy of EGFR-TKI in non-small cell lung cancer harboring EGFR mutations
时间:2020-01-15 11:35:02
DOI:10.4103/0973-1482.153666
作者:Y. Zhang;B. Han;B. Jin
出版源: 《Journal of Cancer Research & Therapeutics》 ,2015 ,26 (suppl 1) :i38-i38
摘要:Abstract OBJECTIVES: Not all the patients harboring epidermal growth factor receptor (EGFR) mutations have a clinical response after the treatment of EGFR-tyrosine kinase inhibitor (TKI). The purpose of the present study was to find whether the baseline carcinoembryonic antigen (CEA) levels were associated with the efficacy of EGFR-TKI in patients harboring EGFR mutations. MATERIALS AND METHODS: Clinical features, serum tumor marker levels, and survival time were analyzed, retrospectively, in 200 non-small cell lung cancer (NSCLC) patients harboring EGFR mutations treated with EGFR-TKI. RESULTS: The total objective response rate (ORR) is 44.0% and disease control rate is 84.5%. The disease control rate in the patients with high CEA levels was significantly higher than that with low CEA levels (88.3 vs 74.5%, P = 0.029). There was no significant difference in progression-free survival (PFS) between high (≥5 ng/ml) and normal CEA groups ( ng/ml) were independent predictive factors for PFS (HR = 1.412, 93% CI: 1.042-1.913, P = 0.026). CONCLUSIONS: Baseline serum CEA levels can serve as predictive factors for the treatment of EGFR-TKI in NSCLC patients harboring EGFR mutations.
大小:169 kb
下载: 点击下载
预览:

浏览器不支持嵌入PDF阅读,打开新页面在线阅读

本页内容由网络收集而来,版权归原创者所有,如有侵权请及时联系